- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 515/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups , or in which the condensed system contains four or more hetero rings
Patent holdings for IPC class C07D 515/22
Total number of patents in this class: 183
10-year publication summary
|
5
|
5
|
9
|
11
|
23
|
19
|
24
|
19
|
16
|
17
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Pharma Mar, S.A. | 214 |
20 |
| Janssen Pharmaceutica N.V. | 3160 |
16 |
| Vertex Pharmaceuticals Incorporated | 1575 |
7 |
| Genzyme Corporation | 1383 |
7 |
| AstraZeneca AB | 2824 |
6 |
| Zeno Management, Inc. | 34 |
6 |
| NATCO Pharma Limited | 204 |
5 |
| Sionna Therapeutics, Inc. | 30 |
5 |
| The Regents of the University of Michigan | 5023 |
4 |
| Abbvie Inc. | 1799 |
4 |
| AbbVie Deutschland GmbH & Co. KG | 255 |
4 |
| Jiangsu Hengrui Medicine Co., Ltd. | 685 |
4 |
| Inflazome Limited | 84 |
4 |
| Ascentage Pharma (Suzhou) Co., Ltd. | 230 |
4 |
| Ascentage Pharma Group Corp Limited | 151 |
4 |
| F. Hoffmann-La Roche AG | 7800 |
3 |
| Hoffmann-La Roche Inc. | 3825 |
3 |
| Gilead Sciences, Inc. | 2242 |
3 |
| Shanghai Hengrui Pharmaceutical Co., Ltd. | 718 |
3 |
| Duality Biologics (Shanghai) Co., Ltd. | 21 |
3 |
| Other owners | 68 |